|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:pembrolizumab
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L01XE29
|
|
gptkbp:brand
|
gptkb:Lenvima
|
|
gptkbp:CASNumber
|
417716-92-8
|
|
gptkbp:category
|
antineoplastic agent
|
|
gptkbp:chemicalFormula
|
C21H19ClN4O4
|
|
gptkbp:contraindication
|
pregnancy
uncontrolled hypertension
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Eisai
|
|
gptkbp:eliminationHalfLife
|
28 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lenvatinib
|
|
gptkbp:KEGGID
|
D09902
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits FGFR
inhibits KIT
inhibits PDGFRα
inhibits RET
inhibits VEGFR
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
426.85 g/mol
|
|
gptkbp:patent
|
gptkb:Eisai
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
9823820
CHEMBL2105758
DB09078
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
vomiting
diarrhea
fatigue
hypertension
weight loss
proteinuria
arthralgia
decreased appetite
stomatitis
|
|
gptkbp:synonym
|
gptkb:E7080
|
|
gptkbp:UNII
|
4A6I0XFS4E
|
|
gptkbp:usedFor
|
gptkb:cancer
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|